xCT as a Predictor for Survival in a Population-Based Cohort of Head and Neck Squamous Cell Carcinoma

被引:0
|
作者
Nissi, Linda [1 ,2 ,3 ]
Tuominen, Sanni [4 ,5 ]
Routila, Johannes [3 ,6 ]
Huusko, Teemu [3 ,6 ]
Ketonen, Petra [4 ,5 ]
Sundvall, Maria [1 ,2 ,3 ,7 ]
Leivo, Ilmo [3 ,8 ]
Irjala, Heikki [3 ,6 ]
Minn, Heikki [1 ,2 ,3 ]
Gronroos, Tove J. [1 ,4 ,5 ]
Ventela, Sami [6 ,9 ]
机构
[1] Turku Univ Hosp, Dept Oncol, Turku, Finland
[2] Turku Univ Hosp, FICAN West Canc Ctr, Turku, Finland
[3] Univ Turku, Turku, Finland
[4] Univ Turku, Preclin Imaging Turku PET Ctr, Turku, Finland
[5] Univ Turku, Med Res Lab, Turku, Finland
[6] Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland
[7] Univ Turku, Inst Biomed, Canc Res Unit, Turku, Finland
[8] Turku Univ Hosp, Dept Pathol, Turku, Finland
[9] Univ Turku, Turku Biosci Ctr, Turku, Finland
来源
CANCER MEDICINE | 2024年 / 13卷 / 21期
关键词
CYSTEINE/GLUTAMATE TRANSPORTER; CISPLATIN RESISTANCE; CANCER-CELLS; FOLLOW-UP; FERROPTOSIS; BIOMARKER; SLC7A11; SULFASALAZINE; SUPPRESSION; RECURRENCE;
D O I
10.1002/cam4.70371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: xCT, also known as SLC7A11 (solute carrier Family 7 Member 11), is a cystine/glutamate antiporter protein that mediates regulated cell death and antioxidant defense. The aim of this study was to investigate the effect of xCT on the outcome of patients diagnosed with new head and neck squamous cell carcinoma (HNSCC). Methods: This retrospective cohort study utilized a population-based dataset, comprising all patients (n = 1033) diagnosed with new HNSCC during 2005-2015 in a population of 697,000 people. All patients (n = 585) with a tumor tissue sample available for immunohistochemical (IHC) staining were included. The follow-up rates were 97% and 81% at 3 and 5 years, respectively. Also, the specificity of the anti-xCT antibody was validated. Results: The expression level and prognostic significance of xCT were strongly dependent on tumor location. In oropharyngeal squamous cell carcinoma (OPSCC) patients, xCT expression was a significant prognostic factor for 5-year overall survival (OAS) (HR: 2.71; 95% CI 1.67-4.39; p < 0.001), disease-specific survival (DSS) (HR: 2.58; 95% CI 1.47-4.54; p = 0.001), and disease-free survival (DFS) (HR: 2.69; 95% CI 1.55-4.64; p < 0.001). Five-year survival rates for OPSCC patients with high and low levels of xCT were OAS 34% versus 62%; DSS 51% versus 73%; DFS 43% versus 73%, respectively. According to a multivariate model adjusted for age, T-class, nodal positivity, and tobacco consumption, xCT was an independent prognostic factor for 3-year survival, in which it outperformed p16 IHC. Similar associations were not observed in squamous cell carcinomas of oral cavity or larynx. Regarding treatment modalities, xCT was most predictive in HNSCC patients who received radiotherapy. Conclusions: High xCT expression was associated with poor prognosis in OPSCC. Our findings suggest that joint analysis of xCT and p16 may add significant value in OPSCC treatment stratification.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study
    Quimby, Alexandra E.
    Lebo, Nicole L.
    Griffiths, Rebecca
    Hall, Stephen
    Dimitroulakos, Jim
    Johnson-Obaseki, Stephanie
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2018, 47
  • [2] Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study
    Alexandra E. Quimby
    Nicole L. Lebo
    Rebecca Griffiths
    Stephen Hall
    Jim Dimitroulakos
    Stephanie Johnson-Obaseki
    Journal of Otolaryngology - Head & Neck Surgery, 47
  • [3] Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma
    Roberti, Elisabetta
    Merlano, Marco
    Ravanelli, Marco
    Alberti, Andrea
    Esposito, Andrea
    Gili, Riccardo
    Spinazze, Silvia
    Bare, Cristina
    Jocolle, Genny
    Benasso, Marco
    Bertolotti, Francesca
    Vecchio, Stefania
    Bacigalupo, Almalina
    Licitra, Lisa
    Denaro, Nerina
    Damico, Mauro
    Lorini, Luigi
    Gurizzan, Cristina
    Alfieri, Salvatore
    Bossi, Paolo
    ORAL ONCOLOGY, 2023, 145
  • [4] Distant metastasis in head and neck squamous cell carcinoma variants: A population-based study
    Takenaka, Yukinori
    Uno, Atsuhiko
    Tanaka, Hidenori
    Takemoto, Norihiko
    Inohara, Hidenori
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2023, 45 (04): : 882 - 889
  • [5] Sarcomatoid Carcinoma in the Head and Neck: A Population-Based Analysis of Outcome and Survival
    Ding, Lin
    Bi, Zhuo-Fei
    Yuan, Hang
    Zhao, Xiao-Hui
    Guan, Xue-Dan
    Yao, He-Rui
    Liu, Yi-Min
    LARYNGOSCOPE, 2021, 131 (02): : E489 - E499
  • [6] Time to first relapse as an outcome and as a predictor of survival in patients with squamous cell carcinoma of the head and neck
    Hall, S
    Groome, P
    Rothwell, D
    1ST WORLD CONGRESS ON HEAD AND NECK ONCOLOGY, 1998, : 1185 - 1188
  • [7] Time to first relapse as an outcome and a predictor of survival in patients with squamous cell carcinoma of the head and neck
    Hall, SF
    Groome, PA
    Rothwell, D
    LARYNGOSCOPE, 2000, 110 (12): : 2041 - 2046
  • [8] Utility of Surgery/Radiotherapy in Distant Metastatic Head and Neck Squamous Cell Carcinoma: A Population-Based Approach
    Patel, Tapan D.
    Marchiano, Emily
    Chin, Oliver Y.
    Kilic, Suat
    Eloy, Jean Anderson
    Baredes, Soly
    Park, Richard Chan Woo
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2016, 154 (05) : 868 - 874
  • [9] A Population-Based Case-Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma
    Liang, Caihua
    McClean, Michael D.
    Marsit, Carmen
    Christensen, Brock
    Peters, Edward
    Nelson, Heather H.
    Kelsey, Karl T.
    CANCER PREVENTION RESEARCH, 2009, 2 (08) : 759 - 768
  • [10] Simple predictors of survival in head and neck squamous cell carcinoma
    Medow, MA
    Weed, HG
    Schuller, DE
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2002, 128 (11) : 1282 - 1286